12 months data from KEYNOTE-799 confirm promising response rates with pembrolizumab in combination with chemo-radiation therapy for locally advanced NSCLC

Updated results from the ongoing phase 2 study KEYNOTE-799 presented at WCLC 2020 show that the addition of pembrolizumab to concurrent chemoradiation therapy (cCRT) in patients with unresectable stage IIIA-C NSCLC provides an objective response rate (ORR) of 69.6% for cohort A (squamous/non-squamous) and 70.5% B (non-squamous).